Novavax Inc:Results From Novavax Nanoflu Influenza Vaccine Phase 3 Clinical Trial Published In Lancet Infectious Diseases.Novavax - Results From Nanoflu Influenza Vaccine Phase 3 Clinical Trial Achieved All Primary Endpoints.Novavax Inc - Nanoflu Vaccine Candidate Induced Significantly Enhanced Cell-Mediated Immune Responses.Novavax Inc - Nanoflu Was Well-Tolerated With A Comparable Safety Profile.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments